A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
NCT05441501
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
39
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostatic Neoplasms
Interventions
DRUG:
JNJ-80038114
Sponsor
Janssen Research & Development, LLC